ES2118677T1 - Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion. - Google Patents

Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.

Info

Publication number
ES2118677T1
ES2118677T1 ES96921197T ES96921197T ES2118677T1 ES 2118677 T1 ES2118677 T1 ES 2118677T1 ES 96921197 T ES96921197 T ES 96921197T ES 96921197 T ES96921197 T ES 96921197T ES 2118677 T1 ES2118677 T1 ES 2118677T1
Authority
ES
Spain
Prior art keywords
active agent
composition
pct
glass
vitrificing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES96921197T
Other languages
English (en)
Other versions
ES2118677T3 (es
Inventor
Ake Lindahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioglan AB
Original Assignee
Bioglan AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan AB filed Critical Bioglan AB
Publication of ES2118677T1 publication Critical patent/ES2118677T1/es
Application granted granted Critical
Publication of ES2118677T3 publication Critical patent/ES2118677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

FORMULACION BIOLOGICAMENTE ACTIVA COMPUESTA DE UNA SOLUCION DE UN AGENTE ACTIVO DISUELTO EN UN VEHICULO VITRIFICANTE, QUE CONTIENE UNA SUSTANCIA VITRIFICANTE (A) CON UN PLASTIFICANTE (B) CUYA CANTIDAD DEBE SELECCIONARSE PREFERIBLEMENTE DE FORMA QUE LA FORMULACION ADQUIERA UNA CONSISTENCIA NO SOLIDA. LA FORMULACION PUEDE PREPARARSE DISOLVIENDO EL AGENTE ACTIVO EN UNA MEZCLA FUNDIDA DE LA SUSTANCIA VITRIFICANTE Y EL PLASTIFICANTE A UNA TEMPERATURA INFERIOR A LA TEMPERATURA DE DESINTEGRACION DEL AGENTE ACTIVO REFERIDO. UTILIZACION DEL VEHICULO VITRIFICANTE PARA LA DISOLUCION DE UN AGENTE BIOLOGICAMENTE ACTIVO.
ES96921197T 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion. Expired - Lifetime ES2118677T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof

Publications (2)

Publication Number Publication Date
ES2118677T1 true ES2118677T1 (es) 1998-10-01
ES2118677T3 ES2118677T3 (es) 2001-10-16

Family

ID=20398685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96921197T Expired - Lifetime ES2118677T3 (es) 1995-06-20 1996-06-19 Una composicion que comprende un agente activo disuelto en un vehiculo formador de vidrio y un procedimiento para su preparacion.

Country Status (15)

Country Link
US (1) US6083518A (es)
EP (1) EP0833611B1 (es)
JP (1) JP4020331B2 (es)
AT (1) ATE204466T1 (es)
AU (1) AU695622B2 (es)
CA (1) CA2225286C (es)
DE (2) DE833611T1 (es)
DK (1) DK0833611T3 (es)
ES (1) ES2118677T3 (es)
HK (1) HK1008774A1 (es)
NZ (1) NZ311208A (es)
PT (1) PT833611E (es)
SE (1) SE9502244D0 (es)
WO (1) WO1997000670A1 (es)
ZA (1) ZA965237B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4512700B2 (ja) * 2003-06-02 2010-07-28 トーアエイヨー株式会社 アシクロビル含有水溶液製剤
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US8900856B2 (en) 2004-04-08 2014-12-02 Biomatrica, Inc. Integration of sample storage and sample management for life science
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
GB2432528B (en) * 2005-11-29 2011-04-06 Ian Ripley Anti-viral compositions comprising flavanone glycosides and fruit acids
NZ571819A (en) * 2006-03-08 2011-04-29 Nihon Nohyaku Co Ltd External pharmaceutical composition comprising luliconazole and either N-methyl-2-pyrrolidone, propylene carbonate or crotamiton
BRPI0621386B8 (pt) * 2006-03-08 2021-07-13 Nihon Nihyaku Co Ltd composição farmacêutica para o uso externo
JP5184342B2 (ja) 2006-03-08 2013-04-17 日本農薬株式会社 外用の医薬組成物
WO2007147052A2 (en) * 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
KR100721126B1 (ko) 2006-12-28 2007-05-23 (주)바이오앤에이치엔티 모기 기피제 조성물
CN101808638B (zh) 2007-09-05 2012-07-25 宝丽制药股份有限公司 抗真菌组合物
CN101808639B (zh) * 2007-09-05 2012-12-05 宝丽制药股份有限公司 抗真菌医药组合物
KR20100075475A (ko) 2007-09-05 2010-07-02 가부시키가이샤 폴라 파마 의약 조성물
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
JP5421901B2 (ja) * 2008-03-31 2014-02-19 国立大学法人広島大学 エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
HUE032022T2 (en) * 2009-01-09 2017-08-28 Egyt Gyogyszervegyeszeti Gyar Medicinal product with improved effect
JP5654497B2 (ja) 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ，インコーポレイテッド 抗真菌製剤
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101754697B1 (ko) 2009-08-25 2017-07-06 가부시키가이샤 폴라 파마 항진균성 약제학적 조성물
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2011248877B9 (en) 2010-04-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
AU2011293201B2 (en) 2010-08-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2016007111A (es) 2013-12-05 2016-08-11 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
CN106456595A (zh) 2014-02-10 2017-02-22 帕塔拉制药有限责任公司 用于***性病症的肥大细胞稳定剂治疗
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP4242628A3 (en) 2015-12-08 2023-11-08 Biomatrica, INC. Reduction of erythrocyte sedimentation rate
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
WO2019094434A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
EP3706736A4 (en) 2017-11-10 2021-08-11 The Regents of the University of Michigan ASH1L DEGRADATION AGENTS AND METHODS OF TREATMENT THROUGH THEM
US11324729B2 (en) 2017-12-07 2022-05-10 The Regents Of The University Of Michigan NSD family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
CN112533581A (zh) 2018-06-07 2021-03-19 密歇根大学董事会 Prc1抑制剂及用其进行治疗的方法
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
WO2020044114A2 (en) 2018-08-29 2020-03-05 Ftf Pharma Private Limited Methotrexate pharmaceutical composition
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
NL2021864B1 (en) * 2018-10-24 2020-05-13 Seranovo B V Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
US20210379184A1 (en) * 2018-10-24 2021-12-09 SeraNovo B.V. Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
US11084825B2 (en) 2018-12-31 2021-08-10 Biomea Fusion, Llc Substituted pyridines as irreversible inhibitors of menin-MLL interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
SG11202109899VA (en) 2019-03-15 2021-10-28 Unicycive Therapeutics Inc Nicorandil derivatives
CN116113406A (zh) 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
USRE33221E (en) 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0319988A1 (en) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha External dermatological composition
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP3722293B2 (ja) * 1991-12-18 2005-11-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 新規な薬学的固体分散物
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
ES2118677T3 (es) 2001-10-16
ATE204466T1 (de) 2001-09-15
NZ311208A (en) 1999-03-29
HK1008774A1 (en) 1999-05-21
AU6247396A (en) 1997-01-22
WO1997000670A1 (en) 1997-01-09
EP0833611A1 (en) 1998-04-08
CA2225286C (en) 2003-06-10
ZA965237B (en) 1997-01-09
EP0833611B1 (en) 2001-08-22
DE69614689D1 (de) 2001-09-27
JP4020331B2 (ja) 2007-12-12
DE69614689T2 (de) 2002-06-27
SE9502244D0 (sv) 1995-06-20
DK0833611T3 (da) 2001-10-08
CA2225286A1 (en) 1997-01-09
DE833611T1 (de) 1999-01-07
AU695622B2 (en) 1998-08-20
JPH11508250A (ja) 1999-07-21
US6083518A (en) 2000-07-04
PT833611E (pt) 2002-01-30

Similar Documents

Publication Publication Date Title
ES2118677T1 (es) Una composicion que comprende un agente activo disuelto en un vehiculo vitrificante y un procedimiento para su preparacion.
AR015863A1 (es) UNA COMPOSICION COSMEICA QUE COMPRENDE AL MENOS UN FOSFOLIPIDO ORGANICO CAPAZ DE FORMAR BICAPAS EN SOLUCION ACUOSA, AL MENOS UN TENSIOACTIVO ANFOTERO Y AL MENOS UN TENSIOACTIVO NO IONICO, UNA COMPOSICION DE SUMINISTRO PARA COMPONENTES LIPOFíLICOS, UN PROCEDIMIENTO PARA PREPARAR DICHA COMPOSICION DE
NO964939D0 (no) Fremgangsmåte for fremstilling av virkestoffpreparater i form av en fast lösning av virkestoffet i en polymermatriks, samt virkestoffpreparater fremstilt ved hjelp av denne fremgangsmåte
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
CO5070580A1 (es) Formulacion farmaceutica para aerosoles con dos o mas sustancias activas
FI103091B1 (fi) Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi
NZ515230A (en) Fast-dispersing dosage forms containing fish gelatin
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
ES2118263T3 (es) Dispositivo de liberacion que tiene excipientes encapsulados.
ES2146227T3 (es) Composiciones farmaceuticas que contienen nifedipina y procedimiento para su preparacion.
PT801559E (pt) Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
ES2163147T3 (es) Perfeccionamientos de agentes antimicrobianos de accion prolongada o relativos a los mismos.
DE69906982D1 (de) Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
ES2155048T3 (es) Composicion biologicamente activa.
NZ508074A (en) Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
DE69416034T2 (de) Pharmazeutische Zubereitung zur rektalen Verabreichung von pharmakologisch wirksamen Verbindungen
ES2149073B1 (es) Agente atrayente y procedimiento para el control de la polilla euzophera pinguis (haw.).
CO4230071A1 (es) Composicion en barra de gel solida que contiene material antiperspirante, el metodo para fabricarla y el producto obtenido

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 833611

Country of ref document: ES